Adults with obesity receiving tirzepatide 10 mg or 15 mg may be able to maintain most of their weight loss after switching to ...

Two phase 3b trials evaluated the efficacy and safety of tirzepatide or orforglipron for weight maintenance after injectable incretin treatment.

New research presented at the European Congress on Obesity (ECO 2026) in Istanbul, Turkey (12–15 May) and published in The Lancet shows that people who have lost weight using the maximum tolerated ...

Oral orforglipron helped adults maintain clinically meaningful weight loss after prior injectable tirzepatide or semaglutide ...

Medications aren’t lifelong contracts. You can switch from one to another — if it’s safe for you to do so and under the guidance of a healthcare provider, of course. So, if you’re taking tirzepatide ...

High-dose tirzepatide is associated with superior HbA1c reduction and weight loss compared with semaglutide in type 2 diabetes and obesity.

NEW ORLEANS — For people with type 2 diabetes (T2D) inadequately controlled on submaximal dulaglutide (Trulicity) doses, switching to tirzepatide (Mounjaro) produces significantly greater A1c and ...

Please provide your email address to receive an email when new articles are posted on . Adults with obesity and a valid prescription can purchase 2.5 mg and 5 mg single-dose vials of tirzepatide. The ...

Wegovy (semaglutide) and Zepbound (tirzepatide) are commonly prescribed medications for weight management. Semaglutide, the first weekly injectable glucagon-like peptide-1 (GLP-1) receptor agonist, ...

Lilly, the pharmaceutical giant, would love for you to believe that tirzepatide is the silver bullet we've all been waiting for — slashing your diabetes risk by 94% while you shed pounds. But dig a ...

Today, Eli Lilly launched a four-dose, single-patient use KwikPen device for its injectable obesity drug, tirzepatide (Zepbound). The device gives patients an additional, potentially more convenient ...